Chaska C. Walton

The paper compares SNIPR, synNotch, and TRUCK systems for Aβ-targeting cell-based drug delivery in Alzheimer's disease, finding SNIPR and synNotch outperform TRUCK in therapeutic response.

This study evaluates a natural compound (MIC) that reduces tau pathology and microglial reactivity in 3xTgAD mice and rescues working memory, suggesting it as a potential therapeutic for Alzheimer's disease.

This paper demonstrates that a synNotch receptor can target extracellular Aβ aggregates, enabling the production of AD therapies like Lecanemab and Aducanumab in response to these aggregates.

The paper evaluates senolytic therapies in a human neuron AD model, finding Navitoclax's neurotoxicity and NK92's preferential targeting of senescent-like cells.

The paper demonstrates that CARs based on AD antibodies can detect and discriminate between tau and distinct Aβ species, suggesting their potential for targeted AD therapies.

The paper shows that primary neurons can enter mitosis under oncogenic conditions, leading to cell death instead of division, and highlights axonal adaptations during this process.